Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NRG LU005
Previous Study | Return to List | Next Study

Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03811002
Recruitment Status : Recruiting
First Posted : January 21, 2019
Last Update Posted : December 5, 2019
Sponsor:
Collaborator:
NRG Oncology
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving chemoradiation with or without atezolizumab may work better in treating patients with limited stage small cell lung cancer.

Condition or disease Intervention/treatment Phase
Limited Stage Lung Small Cell Carcinoma Stage I Lung Cancer AJCC v8 Stage IA1 Lung Cancer AJCC v8 Stage IA2 Lung Cancer AJCC v8 Stage IA3 Lung Cancer AJCC v8 Stage IB Lung Cancer AJCC v8 Stage II Lung Cancer AJCC v8 Stage IIA Lung Cancer AJCC v8 Stage IIB Lung Cancer AJCC v8 Stage III Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 Stage IIIC Lung Cancer AJCC v8 Radiation: 3-Dimensional Conformal Radiation Therapy Drug: Atezolizumab Drug: Carboplatin Drug: Cisplatin Drug: Etoposide Radiation: Intensity-Modulated Radiation Therapy Other: Quality-of-Life Assessment Other: Questionnaire Administration Phase 2 Phase 3

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 506 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Actual Study Start Date : May 28, 2019
Estimated Primary Completion Date : December 28, 2026
Estimated Study Completion Date : December 28, 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: Arm I (etoposide, cisplatin, carboplatin, radiation therapy)
Patients receive etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1. Cycles repeat every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo 3D-CRT or IMRT BID for approximately 3 weeks or QD for approximately 6-7 weeks in the absence of disease progression or unacceptable toxicity.
Radiation: 3-Dimensional Conformal Radiation Therapy
Undergo 3D-CRT
Other Names:
  • 3-dimensional radiation therapy
  • 3D CONFORMAL RADIATION THERAPY
  • 3D CRT
  • 3D-CRT
  • Conformal Therapy
  • Radiation Conformal Therapy
  • Radiation, 3D Conformal

Drug: Carboplatin
Given IV
Other Names:
  • Blastocarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Carboplatinum
  • Carbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatinum
  • Paraplatin
  • Paraplatin AQ
  • Paraplatine
  • Platinwas
  • Ribocarbo

Drug: Cisplatin
Given IV
Other Names:
  • Abiplatin
  • Blastolem
  • Briplatin
  • CDDP
  • Cis-diammine-dichloroplatinum
  • Cis-diamminedichloridoplatinum
  • Cis-diamminedichloro Platinum (II)
  • Cis-diamminedichloroplatinum
  • Cis-dichloroammine Platinum (II)
  • Cis-platinous Diamine Dichloride
  • Cis-platinum
  • Cis-platinum II
  • Cis-platinum II Diamine Dichloride
  • Cismaplat
  • Cisplatina
  • Cisplatinum
  • Cisplatyl
  • Citoplatino
  • Citosin
  • Cysplatyna
  • DDP
  • Lederplatin
  • Metaplatin
  • Neoplatin
  • Peyrone''s Chloride
  • Peyrone''s Salt
  • Placis
  • Plastistil
  • Platamine
  • Platiblastin
  • Platiblastin-S
  • Platinex
  • Platinol
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Platinum
  • Platinum Diamminodichloride
  • Platiran
  • Platistin
  • Platosin

Drug: Etoposide
Given IV
Other Names:
  • Demethyl Epipodophyllotoxin Ethylidine Glucoside
  • EPEG
  • Lastet
  • Toposar
  • Vepesid
  • VP 16
  • VP 16-213
  • VP-16
  • VP-16-213
  • VP16

Radiation: Intensity-Modulated Radiation Therapy
Undergo IMRT
Other Names:
  • IMRT
  • Intensity Modulated RT
  • Intensity-Modulated Radiotherapy
  • Radiation, Intensity-Modulated Radiotherapy

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Other: Questionnaire Administration
Ancillary studies

Active Comparator: Arm II (etoposide, cisplatin, carboplatin, radiation therapy)
Patients receive treatment as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 or 2 of each chemotherapy cycle. Cycles repeat every 3 weeks for 17 cycles (1 year) in the absence of disease progression or unacceptable toxicity.
Radiation: 3-Dimensional Conformal Radiation Therapy
Undergo 3D-CRT
Other Names:
  • 3-dimensional radiation therapy
  • 3D CONFORMAL RADIATION THERAPY
  • 3D CRT
  • 3D-CRT
  • Conformal Therapy
  • Radiation Conformal Therapy
  • Radiation, 3D Conformal

Drug: Atezolizumab
Given IV
Other Names:
  • MPDL 3280A
  • MPDL 328OA
  • MPDL-3280A
  • MPDL3280A
  • MPDL328OA
  • RG7446
  • RO5541267
  • Tecentriq

Drug: Carboplatin
Given IV
Other Names:
  • Blastocarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Carboplatinum
  • Carbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatinum
  • Paraplatin
  • Paraplatin AQ
  • Paraplatine
  • Platinwas
  • Ribocarbo

Drug: Cisplatin
Given IV
Other Names:
  • Abiplatin
  • Blastolem
  • Briplatin
  • CDDP
  • Cis-diammine-dichloroplatinum
  • Cis-diamminedichloridoplatinum
  • Cis-diamminedichloro Platinum (II)
  • Cis-diamminedichloroplatinum
  • Cis-dichloroammine Platinum (II)
  • Cis-platinous Diamine Dichloride
  • Cis-platinum
  • Cis-platinum II
  • Cis-platinum II Diamine Dichloride
  • Cismaplat
  • Cisplatina
  • Cisplatinum
  • Cisplatyl
  • Citoplatino
  • Citosin
  • Cysplatyna
  • DDP
  • Lederplatin
  • Metaplatin
  • Neoplatin
  • Peyrone''s Chloride
  • Peyrone''s Salt
  • Placis
  • Plastistil
  • Platamine
  • Platiblastin
  • Platiblastin-S
  • Platinex
  • Platinol
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Platinum
  • Platinum Diamminodichloride
  • Platiran
  • Platistin
  • Platosin

Drug: Etoposide
Given IV
Other Names:
  • Demethyl Epipodophyllotoxin Ethylidine Glucoside
  • EPEG
  • Lastet
  • Toposar
  • Vepesid
  • VP 16
  • VP 16-213
  • VP-16
  • VP-16-213
  • VP16

Radiation: Intensity-Modulated Radiation Therapy
Undergo IMRT
Other Names:
  • IMRT
  • Intensity Modulated RT
  • Intensity-Modulated Radiotherapy
  • Radiation, Intensity-Modulated Radiotherapy

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Other: Questionnaire Administration
Ancillary studies




Primary Outcome Measures :
  1. Progression-free survival (PFS) (Phase II) [ Time Frame: Time from randomization to any documented progression or death due to any cause, whichever occurs first, assessed up to 5 years ]
    Progressive disease (PD) will be determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Will compare the distributions of PFS between treatment arms using a one-sided stratified log-rank test in all randomized eligible patients. The rates at various timepoints (e.g., every 6 months after randomization) and medians of PFS for each arm will be estimated using the Kaplan-Meier method (1958). The associated 95% confidence interval (CI) will be calculated using Greenwood's formula and based on a log-log transformation applied on the survival function. Results from an unstratified analysis will also be provided.

  2. Overall survival (OS) (Phase III) [ Time Frame: Time from randomization to the date of death due to any cause, assessed up to 5 years ]
    The primary hypotheses for the phase II and III portions will be evaluated by comparing arm 1 to arm 2 based on PFS (phase II) and OS (phase III) using a stratified log-rank test. Hazard ratios will be estimated using a stratified Cox regression model. Event rates over time will be estimated within each treatment group using the Kaplan-Meier method.


Secondary Outcome Measures :
  1. PFS (phase III) [ Time Frame: Time from randomization to any documented progression or death due to any cause, whichever occurs first, assessed up to 5 years ]
    The primary hypotheses for the phase II and III portions will be evaluated by comparing arm 1 to arm 2 based on PFS (phase II) and OS (phase III) using a stratified log-rank test. Hazard ratios will be estimated using a stratified Cox regression model. Event rates over time will be estimated within each treatment group using the Kaplan-Meier method.

  2. Incidence of adverse events [ Time Frame: Up to 5 years ]
    For each patient, the maximum severity reported for both immune mediated and non-immune mediated adverse events will be used in the summaries. Adverse events will be summarized regardless of relationship to protocol treatment as assessed by the investigator. All adverse events, adverse events leading to withdrawal, interruption or modification of protocol treatment, Grade >= 3 adverse events, and serious adverse events will be summarized. Deaths and cause of death will be summarized. The rate of treatment-related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE, v.5.0) will be reported with the frequency and severity (e.g., type, grade, and attribution) by arm, the analysis will be performed at the time of both phase II and phase III (if applicable) primary endpoint analyses. All adverse events will be classified as either immune or non-immune mediated.

  3. Objective response rate (ORR) [ Time Frame: Up to 5 years ]
    Will be defined as the proportion of all randomized subjects whose best overall response (BOR) is either a complete response (CR) or partial response (PR) per RECIST 1.1 criteria. ORR will be compared using a two-sided 5% level Cochran-Mantel Haenszel (CMH) test stratified by the same stratification factors used for randomization. An associated odds ratio and 95% CI will be calculated. The ORR and its corresponding 95% exact CI will also be calculated by Clopper-Pearson for each treatment arm. The difference in ORR between the two treatment arms along with the two-sided 95% CI will be estimated using the following CMH method of weighting, adjusting for the stratification factors.

  4. Local control [ Time Frame: Up to 5 years ]
    Will be defined as freedom from local progression, in which a failure is defined as intrathoracic tumor progression by RECIST 1.1 criteria. Local control will be analyzed as competing risks data based on cause-specific hazards approaches, where deaths without local failure will be considered as a competing event and analyzed as "censoring" of local failure. The rates at various timepoints (e.g., every 6 months after randomization) and medians of PFS for each arm will be estimated using the Kaplan-Meier method (1958). The associated 95% CI will be calculated using Greenwood's formula and based on a log-log transformation applied on the survival function. Results from an unstratified analysis will also be provided.

  5. Distant metastases-free survival (DMFS) [ Time Frame: Time between the date of randomization and the first date of documented distant metastases or death due to any cause, whichever occurs first, assessed up to 5 years ]
    Will compare the distributions of DMFS between treatment arms using a one-sided stratified log-rank test in all randomized eligible patients. The rates at various timepoints (e.g., every 6 months after randomization) and medians of DMFS for each arm will be estimated using the Kaplan-Meier method (1958). The associated 95% CI will be calculated using Greenwood's formula and based on a log-log transformation applied on the survival function. Results from an unstratified analysis will also be provided.

  6. Quality of life (QoL) [ Time Frame: Up to 15 months after the end of the 4th cycle of chemotherapy ]
    Will be measured by the Functional Assessment of Cancer Therapy-Trial Outcome Index (FACT-TOI). Fisher's exact test will be used to compare the proportions of patients experiencing clinically meaningful deterioration (CMD) between the two arms. FACT-TOI deterioration rates and associated 95% confidence interval will be calculated for each treatment group, based on all randomized subjects. Clopper-Pearson method will be used for calculating 95% CI. The deterioration rates of each arm will also be compared using the CMH test, stratified by histology. FACT-TOI at baseline and at each subsequent assessment, as well as their change from baseline will be summarized using descriptive statistics by treatment group as randomized. The scores at baseline and subsequent time points, as well the changes from baseline at each time point for each treatment group will be compared using the two-sample t-test.

  7. Quality-adjusted survival [ Time Frame: Up to 2 years ]
    Assessed using score from the 5-level EuroQol 5-dimensional questionnaire (EQ-5D-5L). Defined as the weighted sum of different time episodes added up to a total quality-adjusted life-year. Subjects' overall health state on a visual analog scale (VAS) at each assessment time point will be summarized using descriptive statistics by treatment group, as randomized. Proportion of subjects reporting problems for the five EQ-5D-5L dimensions at each assessment time point will be summarized by level of problem and by treatment group, as randomized. Percentages will be based on number subjects assessed at assessment time point. Subjects' overall health state on a visual analog scale (EQ-VAS) at each assessment time point will be summarized using descriptive statistics by treatment group, as randomized. Proportion of subjects reporting problems for the five EQ-5D dimensions at each assessment time point will be summarized by level of problem and by treatment group, as randomized.

  8. Level of fatigue [ Time Frame: Up to 2 years ]
    Will be measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). Baseline and PROMIS at each subsequent assessment, as well as their change from baseline will be summarized using descriptive statistics by treatment group as randomized. The change from baseline to subsequent timepoints may be compared between treatment arms using a t-test, or Wilcoxon test if the data is non-normal.

  9. Blood based tumor mutational burden (bTMB) and tissue-based tumor mutational burden (tTMB) [ Time Frame: Up to 5 years ]
    Correlation with clinical outcomes will be done by summarizing the statistical power to detect interaction effects (ratio of hazard ratios) of 0.33 when the marker positive prevalence is 20%, at 2-sided significance level of 0.05.


Other Outcome Measures:
  1. Patient-reported symptomatic toxicities [ Time Frame: Up to 15 months after completion of chemoradiation therapy ]
    Will be measured by Patient Reported Outcomes - Common Terminology Criteria for Adverse Events (PRO-CTCAE). For each symptom and each domain (i.e., frequency, severity, and interference), counts and frequencies will be summarized for the worst score experienced by the patient by treatment arm.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathologically (histologically or cytologically) proven diagnosis of limited stage small cell lung cancer (Stage Tx, T1-T4, N0-3, M0, American Joint Committee on Cancer [AJCC] staging, 8th edition [Ed.]), within 60 days prior to registration
  • Patients must have received one pre-registration cycle of platinum/etoposide chemotherapy prior to study entry, with study registration required within 21 days from day 1 of the pre-registration cycle of chemotherapy and protocol treatment designed to begin 21 days after. If patient has not recovered from pre-registration cycle chemotherapy toxicities, then an additional 14 days is permitted
  • Patients must have had measurable disease (per Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1) prior to the required cycle of platinum/etoposide chemotherapy
  • Minimal staging requirements include:

    • History/physical examination within 30 days prior to registration
    • Positron emission tomography (PET)/computed tomography (CT) scan for staging within 45 days prior to registration
    • CT chest/abdomen with IV contrast (unless contraindicated based on kidney function) within 45 days prior to registration - this can be obtained as part of PET/CT if CT imaging is of diagnostic quality

      • Note: If contrast allergy exists, premedication per institutional guidelines should be performed prior to obtaining CT with contrast. The only exception to this is a documented life-threatening allergy
    • Magnetic resonance imaging (MRI) scan of the brain with contrast (preferred) or CT scan of the brain with contrast (allowable if there is a contraindication with MRI with contrast) within 30 days prior to registration
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 30 days prior to registration
  • Absolute neutrophil count (ANC) >= 1, 500/cells/mm^3 (pre-registration cycle)
  • Platelet count >= 100,000 cells/mm^3 (pre-registration cycle)
  • Hemoglobin >= 9 g/dL (pre-registration cycle)
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) (pre-registration cycle)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.0 x ULN (pre-registration cycle)
  • Glomerular filtration rate (GFR) >= 50 mL/min/1.73 m^2 (within 30 days prior to registration)
  • Patients presenting with a pleural effusion will be eligible if thoracentesis is cytologically negative and non-bloody or if pleural fluid is too small a volume to effectively sample by thoracentesis and does not show increased metabolic activity on CT/PET imaging
  • Negative serum pregnancy test within 14 days of registration for pre-menopausal women of childbearing potential
  • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry

Exclusion Criteria:

  • Definitive clinical or radiologic evidence of metastatic disease
  • Definitive surgical resection of small cell lung cancer
  • Prior invasive malignancy (except non-melanomatous skin cancer, localized prostate cancer, or any early stage cancer treated with curative intent resection) unless disease free for a minimum of 2 years (carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
  • More than 1 cycle of prior platinum-based chemotherapy for SCLC prior to enrollment; note that prior chemotherapy for a different cancer is allowable
  • Any prior atezolizumab or other immunotherapy agent
  • Prior radiotherapy to the lungs or mediastinum that would result in clinically significant overlap of radiation therapy fields; prior tangent fields for breast cancer with minimal overlap with target volumes are allowed per approval of study principal investigators (PIs)
  • Patients with cytologically positive pleural or pericardial fluid are not eligible
  • An active, known or suspected autoimmune disease. Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
  • Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
  • History of allogeneic organ transplant
  • History of primary immunodeficiency
  • Severe, active co-morbidity defined as follows:

    • Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, fatty liver, and inherited liver disease
    • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
    • Active tuberculosis
    • Active hepatitis B (chronic or acute) or hepatitis C infection. Note that if hepatitis status is unknown, hepatitis B/C testing is required

      • Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg]) test, a positive anti-HBc (antibody to hepatitis B core antigen), and a negative viral deoxyribonucleic acid (DNA) test (only obtained if HBsAg is found positive) are eligible
      • Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA). (The HCV RNA test must be performed for patients who have a positive HCV antibody test.)
    • Known immunosuppressive disease, for example history of bone marrow transplant or chronic lymphocytic leukemia (CLL)
    • CD4 count < 200 cells/microliter. Note that patients who are human immunodeficiency virus (HIV) positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration. Note also that HIV testing is not required for eligibility for this protocol
    • Chronic obstructive pulmonary disease (COPD) requiring chronic oral steroid therapy of > 10 mg prednisone daily or equivalent at the time of registration. Inhaled corticosteroids are not exclusionary
    • Unstable angina and/or congestive heart failure requiring hospitalization within the last 3 months
    • Transmural myocardial infarction within the last 3 months
    • Clinically significant interstitial lung disease
  • A condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
  • Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception for the duration of study treatment and for 150 days after the last dose of study drug (Arm 2); this exclusion is necessary because the treatment involved in this study may be significantly teratogenic

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03811002


  Hide Study Locations
Locations
Layout table for location information
United States, Arizona
CTCA at Western Regional Medical Center Recruiting
Goodyear, Arizona, United States, 85338
Contact: Site Public Contact    623-207-3000      
Principal Investigator: Ashish Sangal         
United States, Arkansas
University of Arkansas for Medical Sciences Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Site Public Contact    501-686-8274      
Principal Investigator: Sanjay Maraboyina         
United States, California
University of California Davis Comprehensive Cancer Center Recruiting
Sacramento, California, United States, 95817
Contact: Site Public Contact    916-734-3089      
Principal Investigator: Megan E. Daly         
United States, Colorado
Penrose-Saint Francis Healthcare Recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
United States, Delaware
Helen F Graham Cancer Center Recruiting
Newark, Delaware, United States, 19713
Contact: Site Public Contact    302-623-4450    KDempsey@christianacare.org   
Principal Investigator: Gregory A. Masters         
Medical Oncology Hematology Consultants PA Recruiting
Newark, Delaware, United States, 19713
Contact: Site Public Contact    302-623-4450    KDempsey@christianacare.org   
Principal Investigator: Gregory A. Masters         
United States, Florida
University of Florida Health Science Center - Gainesville Recruiting
Gainesville, Florida, United States, 32610
Contact: Site Public Contact    352-273-8010    cancer-center@ufl.edu   
Principal Investigator: Frederic J. Kaye         
The Watson Clinic Recruiting
Lakeland, Florida, United States, 33805
Contact: Site Public Contact    863-680-7780      
Principal Investigator: Galina Vugman         
UF Cancer Center at Orlando Health Recruiting
Orlando, Florida, United States, 32806
Contact: Site Public Contact    321-841-7246    CancerClinicalTrials@orlandohealth.com   
Principal Investigator: Justin M. Rineer         
United States, Georgia
Grady Health System Recruiting
Atlanta, Georgia, United States, 30303
Contact: Site Public Contact    404-489-9164      
Principal Investigator: Kristin A. Higgins         
Emory University Hospital Midtown Recruiting
Atlanta, Georgia, United States, 30308
Contact: Site Public Contact    888-946-7447      
Principal Investigator: Kristin A. Higgins         
Emory University Hospital/Winship Cancer Institute Recruiting
Atlanta, Georgia, United States, 30322
Contact: Site Public Contact    404-778-1868      
Principal Investigator: Kristin A. Higgins         
Emory Saint Joseph's Hospital Recruiting
Atlanta, Georgia, United States, 30342
Contact: Site Public Contact    404-851-7115      
Principal Investigator: Kristin A. Higgins         
CTCA at Southeastern Regional Medical Center Recruiting
Newnan, Georgia, United States, 30265
Contact: Site Public Contact    770-400-6629      
Principal Investigator: Patricia L. Rich         
Memorial Health University Medical Center Suspended
Savannah, Georgia, United States, 31404
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler Recruiting
Savannah, Georgia, United States, 31405
Contact: Site Public Contact    912-819-5704    underberga@sjchs.org   
Principal Investigator: Howard A. Zaren         
United States, Idaho
Saint Alphonsus Cancer Care Center-Boise Recruiting
Boise, Idaho, United States, 83706
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Saint Alphonsus Cancer Care Center-Caldwell Recruiting
Caldwell, Idaho, United States, 83605
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Saint Alphonsus Medical Center-Nampa Recruiting
Nampa, Idaho, United States, 83686
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
United States, Illinois
Rush - Copley Medical Center Recruiting
Aurora, Illinois, United States, 60504
Contact: Site Public Contact    630-978-6212    Cancer.Research@rushcopley.com   
Principal Investigator: Priyank P. Patel         
Illinois CancerCare-Bloomington Recruiting
Bloomington, Illinois, United States, 61704
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Canton Recruiting
Canton, Illinois, United States, 61520
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Carthage Recruiting
Carthage, Illinois, United States, 62321
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
University of Illinois Recruiting
Chicago, Illinois, United States, 60612
Contact: Site Public Contact    312-355-3046      
Principal Investigator: Lawrence E. Feldman         
Carle on Vermilion Suspended
Danville, Illinois, United States, 61832
Decatur Memorial Hospital Recruiting
Decatur, Illinois, United States, 62526
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Carle Physician Group-Effingham Recruiting
Effingham, Illinois, United States, 62401
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Priyank P. Patel         
Crossroads Cancer Center Recruiting
Effingham, Illinois, United States, 62401
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Elmhurst Memorial Hospital Recruiting
Elmhurst, Illinois, United States, 60126
Contact: Site Public Contact    630-758-5460    Jrohde@emhc.org   
Principal Investigator: Brian C. Myre         
Illinois CancerCare-Eureka Recruiting
Eureka, Illinois, United States, 61530
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Galesburg Recruiting
Galesburg, Illinois, United States, 61401
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Western Illinois Cancer Treatment Center Recruiting
Galesburg, Illinois, United States, 61401
Contact: Site Public Contact    309-344-2831      
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Kewanee Clinic Recruiting
Kewanee, Illinois, United States, 61443
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Macomb Recruiting
Macomb, Illinois, United States, 61455
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Carle Physician Group-Mattoon/Charleston Recruiting
Mattoon, Illinois, United States, 61938
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Priyank P. Patel         
Edward Hospital/Cancer Center Recruiting
Naperville, Illinois, United States, 60540
Contact: Site Public Contact    630-646-6075      
Principal Investigator: Brian C. Myre         
Illinois CancerCare-Ottawa Clinic Recruiting
Ottawa, Illinois, United States, 61350
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Pekin Recruiting
Pekin, Illinois, United States, 61554
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Peoria Recruiting
Peoria, Illinois, United States, 61615
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
OSF Saint Francis Radiation Oncology at Peoria Cancer Center Recruiting
Peoria, Illinois, United States, 61615
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Methodist Medical Center of Illinois Recruiting
Peoria, Illinois, United States, 61636
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
OSF Saint Francis Medical Center Recruiting
Peoria, Illinois, United States, 61637
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Peru Recruiting
Peru, Illinois, United States, 61354
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Edward Hospital/Cancer Center?Plainfield Recruiting
Plainfield, Illinois, United States, 60585
Contact: Site Public Contact    630-646-6075    Cancerresearch@edward.org   
Principal Investigator: Brian C. Myre         
Illinois CancerCare-Princeton Recruiting
Princeton, Illinois, United States, 61356
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Memorial Medical Center Recruiting
Springfield, Illinois, United States, 62781
Contact: Site Public Contact    217-788-3528      
Principal Investigator: Bryan A. Faller         
Carle Cancer Center Recruiting
Urbana, Illinois, United States, 61801
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Priyank P. Patel         
Midwestern Regional Medical Center Recruiting
Zion, Illinois, United States, 60099
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Bruce Gershenhorn         
United States, Indiana
Parkview Regional Medical Center Recruiting
Fort Wayne, Indiana, United States, 46845
Contact: Site Public Contact    877-784-4673      
Principal Investigator: Takefumi Komiya         
Goshen Center for Cancer Care Recruiting
Goshen, Indiana, United States, 46526
Contact: Site Public Contact    574-364-2973    cccois@goshenhealth.com   
Principal Investigator: Sachin Agarwal         
United States, Iowa
McFarland Clinic PC - Ames Recruiting
Ames, Iowa, United States, 50010
Contact: Site Public Contact    515-239-4734    ksoder@mcfarlandclinic.com   
Principal Investigator: Debra M. Prow         
Medical Oncology and Hematology Associates-West Des Moines Suspended
Clive, Iowa, United States, 50325
Mercy Cancer Center-West Lakes Suspended
Clive, Iowa, United States, 50325
Medical Oncology and Hematology Associates-Laurel Suspended
Des Moines, Iowa, United States, 50314
Mercy Medical Center - Des Moines Suspended
Des Moines, Iowa, United States, 50314
Mercy Medical Center-West Lakes Suspended
West Des Moines, Iowa, United States, 50266
United States, Kansas
University of Kansas Cancer Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Fen Wang         
University of Kansas Cancer Center-Overland Park Recruiting
Overland Park, Kansas, United States, 66210
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Fen Wang         
University of Kansas Hospital-Westwood Cancer Center Recruiting
Westwood, Kansas, United States, 66205
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Fen Wang         
Ascension Via Christi Hospitals Wichita Recruiting
Wichita, Kansas, United States, 67214
Contact: Site Public Contact    800-362-0070    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
United States, Kentucky
Norton Hospital Pavilion and Medical Campus Recruiting
Louisville, Kentucky, United States, 40202
Contact: Site Public Contact    502-629-2500      
Principal Investigator: John T. Hamm         
Norton Audubon Hospital and Medical Campus Recruiting
Louisville, Kentucky, United States, 40217
Contact: Site Public Contact    502-629-3465      
Principal Investigator: John T. Hamm         
Norton Brownsboro Hospital and Medical Campus Recruiting
Louisville, Kentucky, United States, 40241
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: John T. Hamm         
United States, Louisiana
LSU Health Baton Rouge-North Clinic Recruiting
Baton Rouge, Louisiana, United States, 70805
Contact: Site Public Contact    225-215-1353    clinicalresearch@marybird.com   
Principal Investigator: David S. Hanson         
Louisiana Hematology Oncology Associates LLC Recruiting
Baton Rouge, Louisiana, United States, 70809
Contact: Site Public Contact    225-215-1353    clinicalresearch@marybird.com   
Principal Investigator: David S. Hanson         
Mary Bird Perkins Cancer Center Recruiting
Baton Rouge, Louisiana, United States, 70809
Contact: Site Public Contact    225-215-1353    clinicalresearch@marybird.com   
Principal Investigator: David S. Hanson         
Our Lady of the Lake Physicians Group - Medical Oncology Recruiting
Baton Rouge, Louisiana, United States, 70809
Contact: Site Public Contact    225-215-1353    clinicalresearch@marybird.com   
Principal Investigator: David S. Hanson         
Medical Center of Baton Rouge Suspended
Baton Rouge, Louisiana, United States, 70816
Mary Bird Perkins Cancer Center - Covington Recruiting
Covington, Louisiana, United States, 70433
Contact: Site Public Contact    225-215-1353    clinicalresearch@marybird.com   
Principal Investigator: David S. Hanson         
Mary Bird Perkins Cancer Center - Houma Recruiting
Houma, Louisiana, United States, 70360
Contact: Site Public Contact    225-215-1353    clinicalresearch@marybird.com   
Principal Investigator: David S. Hanson         
University Medical Center New Orleans Recruiting
New Orleans, Louisiana, United States, 70112
Contact: Site Public Contact    504-210-3539    emede1@lsuhsc.edu   
Principal Investigator: Brian C. Boulmay         
Ochsner Medical Center Jefferson Suspended
New Orleans, Louisiana, United States, 70121
United States, Maine
MaineHealth Coastal Cancer Treatment Center Recruiting
Bath, Maine, United States, 04530
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Matthew D. Cheney         
Waldo County General Hospital Recruiting
Belfast, Maine, United States, 04915
Contact: Site Public Contact    207-338-2500      
Principal Investigator: Matthew D. Cheney         
Stephens Memorial Hospital Recruiting
Norway, Maine, United States, 04268
Contact: Site Public Contact    207-396-8670    OncClinicalResearch@mmc.org   
Principal Investigator: Matthew D. Cheney         
Maine Medical Center-Bramhall Campus Recruiting
Portland, Maine, United States, 04102
Contact: Site Public Contact    207-885-7565      
Principal Investigator: Matthew D. Cheney         
Penobscot Bay Medical Center Recruiting
Rockport, Maine, United States, 04856
Contact: Site Public Contact    207-396-8670    ClinicalResearch@mmc.org   
Principal Investigator: Matthew D. Cheney         
MaineHealth Cancer Care Center of York County Recruiting
Sanford, Maine, United States, 04073
Contact: Site Public Contact    207-459-1600      
Principal Investigator: Matthew D. Cheney         
MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford Recruiting
Sanford, Maine, United States, 04073
Contact: Site Public Contact       LLemire@mmc.org   
Principal Investigator: Matthew D. Cheney         
Maine Medical Center- Scarborough Campus Recruiting
Scarborough, Maine, United States, 04074
Contact: Site Public Contact    207-396-8090    wrighd@mmc.org   
Principal Investigator: Matthew D. Cheney         
Maine Medical Partners - South Portland Recruiting
South Portland, Maine, United States, 04106
Contact: Site Public Contact    207-396-8670    ClinicalResearch@mmc.org   
Principal Investigator: Matthew D. Cheney         
United States, Maryland
Saint Agnes Hospital Recruiting
Baltimore, Maryland, United States, 21229
Contact: Site Public Contact    410-368-2910      
Principal Investigator: Richard S. Hudes         
United States, Massachusetts
UMass Memorial Medical Center - University Campus Recruiting
Worcester, Massachusetts, United States, 01655
Contact: Site Public Contact    508-856-3216    cancer.research@umassmed.edu   
Principal Investigator: William V. Walsh         
United States, Michigan
Saint Joseph Mercy Hospital Recruiting
Ann Arbor, Michigan, United States, 48106
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Christopher M. Reynolds         
McLaren Cancer Institute-Bay City Recruiting
Bay City, Michigan, United States, 48706
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Kiran Devisetty         
Saint Joseph Mercy Brighton Recruiting
Brighton, Michigan, United States, 48114
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Christopher M. Reynolds         
Saint Joseph Mercy Canton Recruiting
Canton, Michigan, United States, 48188
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Christopher M. Reynolds         
Saint Joseph Mercy Chelsea Recruiting
Chelsea, Michigan, United States, 48118
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Christopher M. Reynolds         
21st Century Oncology MHP - Clarkston Suspended
Clarkston, Michigan, United States, 48346
McLaren Cancer Institute-Clarkston Recruiting
Clarkston, Michigan, United States, 48346
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Kiran Devisetty         
Henry Ford Hospital Recruiting
Detroit, Michigan, United States, 48202
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Eleanor M. Walker         
21st Century Oncology MHP - Farmington Suspended
Farmington Hills, Michigan, United States, 48334
McLaren Cancer Institute-Flint Recruiting
Flint, Michigan, United States, 48532
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Kiran Devisetty         
Singh and Arora Hematology Oncology PC Recruiting
Flint, Michigan, United States, 48532
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Kiran Devisetty         
West Michigan Cancer Center Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
McLaren-Greater Lansing Recruiting
Lansing, Michigan, United States, 48910
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Kiran Devisetty         
Mid-Michigan Physicians-Lansing Recruiting
Lansing, Michigan, United States, 48912
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Kiran Devisetty         
Sparrow Hospital Recruiting
Lansing, Michigan, United States, 48912
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Christopher M. Reynolds         
McLaren Cancer Institute-Lapeer Region Recruiting
Lapeer, Michigan, United States, 48446
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Kiran Devisetty         
McLaren Cancer Institute-Macomb Recruiting
Mount Clemens, Michigan, United States, 48043
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Kiran Devisetty         
McLaren Cancer Institute-Northern Michigan Recruiting
Petoskey, Michigan, United States, 49770
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Kiran Devisetty         
McLaren-Port Huron Recruiting
Port Huron, Michigan, United States, 48060
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Kiran Devisetty         
Ascension Saint Mary's Hospital Recruiting
Saginaw, Michigan, United States, 48601
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Christopher M. Reynolds         
Lakeland Medical Center Saint Joseph Recruiting
Saint Joseph, Michigan, United States, 49085
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Marie Yeager Cancer Center Recruiting
Saint Joseph, Michigan, United States, 49085
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
21st Century Oncology MHP - Troy Suspended
Troy, Michigan, United States, 48098
United States, Minnesota
Sanford Joe Lueken Cancer Center Recruiting
Bemidji, Minnesota, United States, 56601
Contact: Site Public Contact    218-333-5000    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
Saint Luke's Hospital of Duluth Recruiting
Duluth, Minnesota, United States, 55805
Contact: Site Public Contact    218-249-7825    kdean@slhduluth.com   
Principal Investigator: Homam Alkaied         
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Site Public Contact    855-776-0015      
Principal Investigator: Helen J. Ross         
Coborn Cancer Center at Saint Cloud Hospital Recruiting
Saint Cloud, Minnesota, United States, 56303
Contact: Site Public Contact    877-229-4907    coborncancercenter@centracare.com   
Principal Investigator: Donald J. Jurgens         
United States, Missouri
Parkland Health Center-Bonne Terre Recruiting
Bonne Terre, Missouri, United States, 63628
Contact: Site Public Contact    314-996-5569      
Principal Investigator: Bryan A. Faller         
Saint Francis Medical Center Recruiting
Cape Girardeau, Missouri, United States, 63703
Contact: Site Public Contact    573-334-2230    sfmc@sfmc.net   
Principal Investigator: Bryan A. Faller         
Capital Region Southwest Campus Suspended
Jefferson City, Missouri, United States, 65109
The University of Kansas Cancer Center-North Recruiting
Kansas City, Missouri, United States, 64154
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Fen Wang         
The University of Kansas Cancer Center-Lee's Summit Recruiting
Lee's Summit, Missouri, United States, 64064
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Fen Wang         
University of Kansas Cancer Center at North Kansas City Hospital Recruiting
North Kansas City, Missouri, United States, 64116
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Fen Wang         
Missouri Baptist Medical Center Recruiting
Saint Louis, Missouri, United States, 63131
Contact: Site Public Contact    314-996-5569      
Principal Investigator: Bryan A. Faller         
Mercy Hospital Saint Louis Recruiting
Saint Louis, Missouri, United States, 63141
Contact: Site Public Contact    314-251-7066      
Principal Investigator: Jay W. Carlson         
Sainte Genevieve County Memorial Hospital Recruiting
Sainte Genevieve, Missouri, United States, 63670
Contact: Site Public Contact    314-996-5569      
Principal Investigator: Bryan A. Faller         
Mercy Hospital Springfield Recruiting
Springfield, Missouri, United States, 65804
Contact: Site Public Contact    417-269-4520      
Principal Investigator: Jay W. Carlson         
Missouri Baptist Sullivan Hospital Recruiting
Sullivan, Missouri, United States, 63080
Contact: Site Public Contact    314-996-5569      
Principal Investigator: Bryan A. Faller         
Missouri Baptist Outpatient Center-Sunset Hills Recruiting
Sunset Hills, Missouri, United States, 63127
Contact: Site Public Contact    314-996-5569      
Principal Investigator: Bryan A. Faller         
United States, Nebraska
CHI Health Saint Francis Suspended
Grand Island, Nebraska, United States, 68803
Nebraska Methodist Hospital Recruiting
Omaha, Nebraska, United States, 68114
Contact: Site Public Contact    402-354-5144      
Principal Investigator: Timothy Dorius         
Alegent Health Bergan Mercy Medical Center Recruiting
Omaha, Nebraska, United States, 68124
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
United States, Nevada
OptumCare Cancer Care at Oakey Recruiting
Las Vegas, Nevada, United States, 89106
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Radiation Oncology Centers of Nevada Central Suspended
Las Vegas, Nevada, United States, 89106
OptumCare Cancer Care at Fort Apache Recruiting
Las Vegas, Nevada, United States, 89148
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Renown Regional Medical Center Suspended
Reno, Nevada, United States, 89502
United States, New Hampshire
New Hampshire Oncology Hematology PA-Concord Recruiting
Concord, New Hampshire, United States, 03301
Contact: Site Public Contact    603-224-2556      
Principal Investigator: Douglas J. Weckstein         
New Hampshire Oncology Hematology PA-Hooksett Recruiting
Hooksett, New Hampshire, United States, 03106
Contact: Site Public Contact    800-339-6484      
Principal Investigator: Douglas J. Weckstein         
United States, New Mexico
University of New Mexico Cancer Center Recruiting
Albuquerque, New Mexico, United States, 87102
Contact: Site Public Contact    505-925-0366    LByatt@nmcca.org   
Principal Investigator: Atul Kumar         
United States, New York
Montefiore Medical Center-Einstein Campus Recruiting
Bronx, New York, United States, 10461
Contact: Site Public Contact    718-379-6866    aaraiza@montefiore.org   
Principal Investigator: Nitin Ohri         
Montefiore Medical Center - Moses Campus Recruiting
Bronx, New York, United States, 10467
Contact: Site Public Contact    718-379-6866    aaraiza@montefiore.org   
Principal Investigator: Nitin Ohri         
Arnot Ogden Medical Center/Falck Cancer Center Recruiting
Elmira, New York, United States, 14905
Contact: Site Public Contact    607-271-7000      
Principal Investigator: Serge Dauphin         
State University of New York Upstate Medical University Recruiting
Syracuse, New York, United States, 13210
Contact: Site Public Contact    315-464-5476      
Principal Investigator: Stephen L. Graziano         
United States, North Carolina
Randolph Hospital Recruiting
Asheboro, North Carolina, United States, 27203
Contact: Site Public Contact    336-832-0836    vivian.sheidler@conehealth.com   
Principal Investigator: Vinay K. Gudena         
Cone Health Cancer Center at Alamance Regional Recruiting
Burlington, North Carolina, United States, 27215
Contact: Site Public Contact    336-538-7725    kaye.shoffner@conehealth.com   
Principal Investigator: Vinay K. Gudena         
Cone Health Cancer Center Recruiting
Greensboro, North Carolina, United States, 27403
Contact: Site Public Contact    336-832-0821    vivian.sheidler@conehealth.com   
Principal Investigator: Vinay K. Gudena         
Margaret R Pardee Memorial Hospital Recruiting
Hendersonville, North Carolina, United States, 28791
Contact: Site Public Contact    828-696-4716    karen.morris@unchealth.unc.edu   
Principal Investigator: James E. Radford         
Novant Health Oncology Specialists-Kernersville Suspended
Kernersville, North Carolina, United States, 27284
Novant Health Oncology Specialists-Mount Airy Suspended
Mount Airy, North Carolina, United States, 27030
FirstHealth of the Carolinas-Moore Regional Hospital Recruiting
Pinehurst, North Carolina, United States, 28374
Contact: Site Public Contact    910-715-3500    jcwilliams@firsthealth.org   
Principal Investigator: Charles S. Kuzma         
Novant Health Oncology Specialists-Statesville Suspended
Statesville, North Carolina, United States, 28625
Novant Health Oncology Specialists-Davidson County Suspended
Thomasville, North Carolina, United States, 27360
Novant Health Oncology Specialists-Wilkesboro Suspended
Wilkesboro, North Carolina, United States, 28659
Novant Health Forsyth Medical Center Suspended
Winston-Salem, North Carolina, United States, 27103
United States, North Dakota
Sanford Bismarck Medical Center Recruiting
Bismarck, North Dakota, United States, 58501
Contact: Site Public Contact    701-323-5760    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
Altru Cancer Center Recruiting
Grand Forks, North Dakota, United States, 58201
Contact: Site Public Contact    701-780-6520      
Principal Investigator: Grant R. Seeger         
United States, Ohio
Summa Health System - Akron Campus Recruiting
Akron, Ohio, United States, 44304
Contact: Site Public Contact    330-375-4221    cancerresearch@summahealth.org   
Principal Investigator: Bradley T. Clifford         
UHHS-Chagrin Highlands Medical Center Recruiting
Beachwood, Ohio, United States, 44122
Contact: Site Public Contact    800-641-2422    CTUReferral@UHhospitals.org   
Principal Investigator: Tithi Biswas         
Aultman Health Foundation Recruiting
Canton, Ohio, United States, 44710
Contact: Site Public Contact    330-363-7274    ClinicalReserachDept@aultman.com   
Principal Investigator: Shruti Trehan         
Adena Regional Medical Center Recruiting
Chillicothe, Ohio, United States, 45601
Contact: Site Public Contact    877-779-7585    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
University of Cincinnati/Barrett Cancer Center Recruiting
Cincinnati, Ohio, United States, 45219
Contact: Site Public Contact    513-558-4553    uchealthnews@uc.edu   
Principal Investigator: Emily C. Daugherty         
Case Western Reserve University Recruiting
Cleveland, Ohio, United States, 44106
Contact: Site Public Contact    800-641-2422    CTUReferral@UHhospitals.org   
Principal Investigator: Tithi Biswas         
Ohio State University Comprehensive Cancer Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Site Public Contact    800-293-5066    Jamesline@osumc.edu   
Principal Investigator: Meng X. Welliver         
Mount Carmel East Hospital Recruiting
Columbus, Ohio, United States, 43213
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Riverside Methodist Hospital Recruiting
Columbus, Ohio, United States, 43214
Contact: Site Public Contact    614-566-4475    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Grant Medical Center Recruiting
Columbus, Ohio, United States, 43215
Contact: Site Public Contact    614-566-4475    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
The Mark H Zangmeister Center Recruiting
Columbus, Ohio, United States, 43219
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Mount Carmel Health Center West Recruiting
Columbus, Ohio, United States, 43222
Contact: Site Public Contact    614-234-5433    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Doctors Hospital Recruiting
Columbus, Ohio, United States, 43228
Contact: Site Public Contact    614-566-3275    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
OhioHealth Mansfield Hospital Recruiting
Mansfield, Ohio, United States, 44903
Contact: Site Public Contact    419-526-8018    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Marietta Memorial Hospital Recruiting
Marietta, Ohio, United States, 45750
Contact: Site Public Contact    800-523-3977    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
UH Seidman Cancer Center at Lake Health Mentor Campus Recruiting
Mentor, Ohio, United States, 44060
Contact: Site Public Contact    800-641-2422    CTUReferral@UHhospitals.org   
Principal Investigator: Tithi Biswas         
UH Seidman Cancer Center at Southwest General Hospital Recruiting
Middleburg Heights, Ohio, United States, 44130
Contact: Site Public Contact    800-641-2422    CTUReferral@UHhospitals.org   
Principal Investigator: Tithi Biswas         
Licking Memorial Hospital Recruiting
Newark, Ohio, United States, 43055
Contact: Site Public Contact    740-348-4000    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
University Hospitals Parma Medical Center Recruiting
Parma, Ohio, United States, 44129
Contact: Site Public Contact    800-641-2422    CTUReferral@UHhospitals.org   
Principal Investigator: Tithi Biswas         
Southern Ohio Medical Center Recruiting
Portsmouth, Ohio, United States, 45662
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
UH Seidman Cancer Center at Firelands Regional Medical Center Recruiting
Sandusky, Ohio, United States, 44870
Contact: Site Public Contact    800-641-2422    CTUReferral@UHhospitals.org   
Principal Investigator: Tithi Biswas         
University Hospitals Sharon Health Center Recruiting
Wadsworth, Ohio, United States, 44281
Contact: Site Public Contact    800-641-2422    CTUReferral@UHhospitals.org   
Principal Investigator: Tithi Biswas         
University Pointe Recruiting
West Chester, Ohio, United States, 45069
Contact: Site Public Contact       clinicaltrials@ucphysicians.com   
Principal Investigator: Emily C. Daugherty         
UH Seidman Cancer Center at Saint John Medical Center Recruiting
Westlake, Ohio, United States, 44145
Contact: Site Public Contact    800-641-2422    CTUReferral@UHhospitals.org   
Principal Investigator: Tithi Biswas         
UHHS-Westlake Medical Center Recruiting
Westlake, Ohio, United States, 44145
Contact: Site Public Contact    800-641-2422    CTUReferral@UHhospitals.org   
Principal Investigator: Tithi Biswas         
Genesis Healthcare System Cancer Care Center Recruiting
Zanesville, Ohio, United States, 43701
Contact: Site Public Contact    740-454-5232    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
United States, Oklahoma
Cancer Centers of Southwest Oklahoma Research Recruiting
Lawton, Oklahoma, United States, 73505
Contact: Site Public Contact    877-231-4440      
Principal Investigator: Vipul Pareek         
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Site Public Contact    405-271-8777    ou-clinical-trials@ouhsc.edu   
Principal Investigator: Vipul Pareek         
Cancer Treatment Centers of America Recruiting
Tulsa, Oklahoma, United States, 74133
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Theodore W. Pollock         
United States, Oregon
Legacy Mount Hood Medical Center Suspended
Gresham, Oregon, United States, 97030
Providence Newberg Medical Center Recruiting
Newberg, Oregon, United States, 97132
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Dan S. Zuckerman         
Legacy Good Samaritan Hospital and Medical Center Suspended
Portland, Oregon, United States, 97210
Providence Portland Medical Center Recruiting
Portland, Oregon, United States, 97213
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Dan S. Zuckerman         
Providence Saint Vincent Medical Center Recruiting
Portland, Oregon, United States, 97225
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Dan S. Zuckerman         
United States, Pennsylvania
Bryn Mawr Hospital Recruiting
Bryn Mawr, Pennsylvania, United States, 19010
Contact: Site Public Contact    484-476-2649    turzoe@mlhs.org   
Principal Investigator: Albert S. DeNittis         
Ephrata Cancer Center Recruiting
Ephrata, Pennsylvania, United States, 17522
Contact: Site Public Contact    717-721-4840      
Principal Investigator: Chanh T. Huynh         
Adams Cancer Center Recruiting
Gettysburg, Pennsylvania, United States, 17325
Contact: Site Public Contact    877-441-7957      
Principal Investigator: Chanh T. Huynh         
Cherry Tree Cancer Center Recruiting
Hanover, Pennsylvania, United States, 17331
Contact: Site Public Contact    877-441-7957      
Principal Investigator: Chanh T. Huynh         
Lancaster General Hospital Recruiting
Lancaster, Pennsylvania, United States, 17604
Contact: Site Public Contact    717-544-5511      
Principal Investigator: Samuel J. Kerr         
Sechler Family Cancer Center Recruiting
Lebanon, Pennsylvania, United States, 17042
Contact: Site Public Contact    717-741-8303    doxenberg@wellspan.org   
Principal Investigator: Chanh T. Huynh         
Riddle Memorial Hospital Recruiting
Media, Pennsylvania, United States, 19063
Contact: Site Public Contact    484-476-2649    turzoe@mlhs.org   
Principal Investigator: Albert S. DeNittis         
Bryn Mawr Health Center Recruiting
Newtown Square, Pennsylvania, United States, 19073
Contact: Site Public Contact    484-476-2649    turzoe@mlhs.org   
Principal Investigator: Albert S. DeNittis         
Paoli Memorial Hospital Recruiting
Paoli, Pennsylvania, United States, 19301
Contact: Site Public Contact    484-476-2649    turzoe@mlhs.org   
Principal Investigator: Albert S. DeNittis         
Thomas Jefferson University Hospital Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Site Public Contact    215-955-6084      
Principal Investigator: Maria Werner-Wasik         
Eastern Regional Medical Center Recruiting
Philadelphia, Pennsylvania, United States, 19124
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Shayma M. Kazmi         
Guthrie Medical Group PC-Robert Packer Hospital Recruiting
Sayre, Pennsylvania, United States, 18840
Contact: Site Public Contact    800-836-0388      
Principal Investigator: Thomas J. Gergel         
Reading Hospital Recruiting
West Reading, Pennsylvania, United States, 19611
Contact: Site Public Contact    610-988-9323      
Principal Investigator: Terrence P. Cescon         
Lankenau Medical Center Recruiting
Wynnewood, Pennsylvania, United States, 19096
Contact: Site Public Contact    484-476-2649    turzoe@mlhs.org   
Principal Investigator: Albert S. DeNittis         
WellSpan Health-York Cancer Center Recruiting
York, Pennsylvania, United States, 17403
Contact: Site Public Contact    877-441-7957      
Principal Investigator: Chanh T. Huynh         
United States, South Carolina
Gibbs Cancer Center-Pelham Recruiting
Greer, South Carolina, United States, 29651
Contact: Site Public Contact    864-560-6104    kmertz-rivera@gibbscc.org   
Principal Investigator: Abderrahim Khomani         
Spartanburg Medical Center Recruiting
Spartanburg, South Carolina, United States, 29303
Contact: Site Public Contact    864-560-6104    kmertz-rivera@gibbscc.org   
Principal Investigator: Abderrahim Khomani         
United States, South Dakota
Rapid City Regional Hospital Recruiting
Rapid City, South Dakota, United States, 57701
Contact: Site Public Contact    605-716-3982    research@rcrh.org   
Principal Investigator: Michael J. Swartz         
Sanford Cancer Center Oncology Clinic Recruiting
Sioux Falls, South Dakota, United States, 57104
Contact: Site Public Contact    605-312-3320    OncologyClinicTrialsSF@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
Sanford USD Medical Center - Sioux Falls Recruiting
Sioux Falls, South Dakota, United States, 57117-5134
Contact: Site Public Contact    605-312-3320    OncologyClinicalTrialsSF@SanfordHealth.org   
Principal Investigator: Preston D. Steen         
United States, Tennessee
Thompson Cancer Survival Center Recruiting
Knoxville, Tennessee, United States, 37916
Contact: Site Public Contact    865-331-1812      
Principal Investigator: Grant M. Clark         
United States, Virginia
University of Virginia Cancer Center Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Site Public Contact    434-243-6303    PAS9E@virginia.edu   
Principal Investigator: Richard D. Hall         
Augusta Health Center for Cancer and Blood Disorders Recruiting
Fishersville, Virginia, United States, 22939
Contact: Site Public Contact    540-332-5960      
Principal Investigator: Kelvin B. Raybon         
United States, Washington
Providence Regional Cancer System-Aberdeen Recruiting
Aberdeen, Washington, United States, 98520
Contact: Site Public Contact    360-412-8958    deidre.dillon@providence.org   
Principal Investigator: Dan S. Zuckerman         
Harrison Medical Center Recruiting
Bremerton, Washington, United States, 98310
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Legacy Salmon Creek Hospital Suspended
Vancouver, Washington, United States, 98686
United States, West Virginia
Wheeling Hospital/Schiffler Cancer Center Recruiting
Wheeling, West Virginia, United States, 26003
Contact: Site Public Contact    304-243-6442      
Principal Investigator: Jondavid Pollock         
United States, Wisconsin
Langlade Hospital and Cancer Center Recruiting
Antigo, Wisconsin, United States, 54409
Contact: Site Public Contact    715-623-9869    Juli.Alford@aspirus.org   
Principal Investigator: Harish G. Ahuja         
Mayo Clinic Health System-Eau Claire Clinic Recruiting
Eau Claire, Wisconsin, United States, 54701
Contact: Site Public Contact    855-776-0015      
Principal Investigator: Helen J. Ross         
Gundersen Lutheran Medical Center Recruiting
La Crosse, Wisconsin, United States, 54601
Contact: Site Public Contact    608-775-2385    cancerctr@gundersenhealth.org   
Principal Investigator: Collin D. Driscoll         
Mayo Clinic Health System-Franciscan Healthcare Recruiting
La Crosse, Wisconsin, United States, 54601
Contact: Site Public Contact    855-776-0015      
Principal Investigator: Helen J. Ross         
University of Wisconsin Hospital and Clinics Recruiting
Madison, Wisconsin, United States, 53792
Contact: Site Public Contact    800-622-8922      
Principal Investigator: Andrew M. Baschnagel         
Zablocki Veterans Administration Medical Center Recruiting
Milwaukee, Wisconsin, United States, 53295
Contact: Site Public Contact    888-469-6614      
Principal Investigator: Elizabeth M. Gore         
Aspirus Regional Cancer Center Recruiting
Wausau, Wisconsin, United States, 54401
Contact: Site Public Contact    877-405-6866      
Principal Investigator: Harish G. Ahuja         
Sponsors and Collaborators
National Cancer Institute (NCI)
NRG Oncology
Investigators
Layout table for investigator information
Principal Investigator: Kristin A Higgins NRG Oncology

Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03811002     History of Changes
Other Study ID Numbers: NCI-2019-00178
NCI-2019-00178 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
NRG-LU005 ( Other Identifier: NRG Oncology )
NRG-LU005 ( Other Identifier: CTEP )
U10CA180868 ( U.S. NIH Grant/Contract )
First Posted: January 21, 2019    Key Record Dates
Last Update Posted: December 5, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
URL: https://grants.nih.gov/policy/sharing.htm

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Small Cell Lung Carcinoma
Carcinoma, Small Cell
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Cisplatin
Carboplatin
Etoposide
Etoposide phosphate
Atezolizumab
Antibodies, Monoclonal
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs